First Nebraska Trust Co Takes Position in Boston Scientific Corporation $BSX

Key Points

• First Nebraska Trust Co. acquired 115,159 Boston Scientific shares in the second quarter, valued at approximately $4.9 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific insiders bought 194,522 shares worth about $9.4 million over the past three months, including substantial purchases by CEO Michael Mahoney and director David Habiger.
• The company reported quarterly EPS of $0.86, exceeding estimates, while revenue rose 7.5% year over year to $5.44 billion. Analysts maintain a “Moderate Buy” consensus with an average price target of $71.62, and Boston Scientific authorized a $5 billion share-repurchase plan.

First Nebraska Trust Co bought a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 115,159 shares of the medical equipment provider's stock, valued at approximately $4,915,000.

A number of other large investors have also recently made changes to their positions in BSX. Renaissance Group LLC bought a new position in Boston Scientific during the 4th quarter valued at $28,064,000. Perigon Wealth Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $883,000. Y Intercept Hong Kong Ltd lifted its position in shares of Boston Scientific by 148.8% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider's stock valued at $47,816,000 after buying an additional 670,060 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab grew its stake in shares of Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider's stock worth $13,659,000 after acquiring an additional 28,961 shares during the period. Finally, Meiji Yasuda America Inc purchased a new stake in Boston Scientific in the 4th quarter worth about $4,708,000. 89.07% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director David C. Habiger purchased 2,100 shares of the business's stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 194,522 shares of company stock worth $9,385,210 in the last three months. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Zacks Research lowered shares of Boston Scientific from a "hold" rating to a "strong sell" rating in a research report on Friday, June 5th. Leerink Partners set a $60.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Jefferies Financial Group dropped their price target on shares of Boston Scientific from $100.00 to $67.00 and set a "buy" rating on the stock in a research note on Wednesday, June 24th. Bank of America cut their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a "buy" rating for the company in a report on Monday, May 18th. Finally, BTIG Research reduced their price objective on shares of Boston Scientific from $65.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $71.62.

Boston Scientific Trading Up 2.1%

Shares of BSX opened at $50.39 on Friday. The business's 50-day moving average price is $46.34 and its 200-day moving average price is $57.86. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The stock has a market cap of $73.03 billion, a PE ratio of 20.40, a P/E/G ratio of 1.10 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific's revenue was up 7.5% compared to the same quarter last year. During the same period last year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's leadership believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source